% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Sep 11, 2013 1:24 PM Flag

    Another poor presentation by Junius

    Too much ftalk about side effects. He should be banned from ever using the term monetization again, it's a stupid idea, stop talking about it already. Very little information regarding progress, data, efficacy. He clearly is not the best person for this job and needs to be replaced IMO.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I listened to the web cast from the Immunogen web site. I actually think Junius did a very good job with his presentation. He addressed the toxicity concerns exactly as he should have and reminded these nubes that the early clinical trials are meant to find the highest tolerable doses for these drugs, and to do that you have to find the intolerable dose for these drugs. They are dose escalation studies, so duh, were going to find doses that have significant adverse events. I hope that puts and end to the questions surrounding the dosing of 901. He only mentioned monetization of Kadcyla roylaties as a financing option should they ever need it. Just referred to it as another tool they have, but there current cash position and royalty stream was sufficient for their current needs. I'm not a big Junius fan given some of his previous presentations, but this one was quite good I thought.

      Chinese Hamsters

      • 1 Reply to chinesehamsters
      • OK, thanks CH, I read the transcript, did not listen. Agreed, the tox BS was a bio-short hedge fund trick to cause selling. Not sure who would be so dumb to buy that short story, but someone did, price went from $20+ to below $15. Still hoping for a new CEO, not CFO, but it's probably not happening. Is it just me, or do they take forever to find the max and optimal dose and advance from phase I to phase II? Hoping 289 moves quickly to gain the new FDA designation for rapid development and approval.

6.17+0.06(+0.98%)May 4 4:00 PMEDT